Future Science Group
Browse
FON-2022-0481 Infographic.pdf (2.92 MB)
Download file

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors Infographic

Download (2.92 MB)
figure
posted on 2022-11-15, 15:42 authored by Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Lisle M Nabell, DeLisa Madere, Emma Chacon, Christina Spencer, Li Li, Christopher Larson, Tony Reid, Scott Caroen, Bryan Oronsky, Meaghan Stirn, Jeannie Williams, Minal A Barve

BETA PRIME: Phase I study of AdAPT-001 as

monotherapy and combined with a

checkpoint inhibitor in superficially

accessible, treatment-refractory solid tumors Infographic

Funding

EpicentRx, Inc. is the clinical trial sponsor. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    abscopal effectAdAPT-001BETA PRIMEoncolytic adenovirussolid tumorsstudy protocolTGF-β trap

    Licence

    CC BY 4.0

    Exports